传染性软疣治疗药物——Ycanth

Molluscum contagiosum treatment drug:Ycanth

传染性软疣因痘病毒科中的传染性软疣病毒感染所致,属于儿童常见的皮肤病毒感染性疾病。斑蝥素治疗软疣历史长达60余年,临床疗效已得到认可。长期以来,斑蝥素存在使用上的局限性,如制剂标准化不足、浓度和治疗持续时间不统一标准、使用繁杂等。2023年7月21日,FDA批准Ycanth(活性成分:斑蝥素)上市,该药为首个用于成人、2岁及以上儿童的软疣局部治疗药物。Ycanth的优点是制造规范、有效浓度恒定和使用便捷,且保持了良好的临床疗效。本文就其药理作用、药动学、临床疗效、安全性、药物相互作用及用法用量等进行综述。

Molluscum contagiosum caused by the contagious molluscum contagiosum virus infection in the Poxviridae family,is the most common viral skin infection in children.Cantharidin has a history of over 60 years in treating molluscum contagiosum,and its clinical effectiveness has been recognized.However,cantharidin has long been associated with limitations in its use,such as inadequate standardization of formulations,inconsistent concentrations,varying treatment durations,and complexity in application.On July 21,2023,the U.S.FDA approved Ycanth(active ingredient:cantharidin)for market release.This drug is the first topical treatment for molluscum contagiosum in adults and children aged 2 and above.Ycanth offers advantages in terms of standardized manufacturing,consistent effective concentrations,and ease of use,while maintaining excellent clinical efficacy.This article provides a comprehensive review of its pharmacological action,pharmacokinetics,clinical evaluation,safety,drug interactions,and dosage and administration.